# 5 reasons to back the future of anaphylaxis care | Sempresto

- Canonical URL: https://wefunder.com/feed/402085
- Entity ID: wefunder:feed_item:402085
- Published at: 2026-10-06 16:03:24 UTC
- Updated at: 2026-10-06 16:03:24 UTC

## Author
Elizabeth Reczek

## Subject
Sempresto

## Content
Hi everyone,Five years ago, Sempresto couldn't have existed because we would have needed a custom case or a permanent mount. Then MagSafe/Qi2 became standard and changed that overnight.That timing is part of why I believe this is the right moment. If you've been meaning to invest, here's what else lines up for us to get Sempresto out and into the hands of every allergy family: 🎯 A streamlined regulatory pathway designed to bring innovative drug delivery to market fast. Our Type B Pre-IND meeting is complete, with the 505(b)(2) pathway confirmed. We're relying on decades of existing epinephrine safety data instead of starting from zero. No new clinical efficacy trials are currently anticipated. Targeting a 2028 launch.🔬 Invented by a physician whose own daughter struggled to carry her epinephrine. Our core technology comes from Dr. Edmund Pribitkin, a practicing physician at Jefferson Health and my co-founder. Protected by 15 issued patents, 10 more pending.🏆 Recognized before we've even launched. This year alone: a prestigious 2026 Red Dot Design Award and a strategic partnership with Thomas Jefferson University.💰 Backed by proven conviction. Angel Dominic J. Frederico has committed $2.5M to lead this round. Our team has led 3 IPOs and 30+ business development transactions in medtech.📈 A market that isn't going anywhere. $3B+ addressable market. 33 million Americans live with food allergies, most of them carrying a device that hasn't changed in decades.When someone I love has an allergic reaction, I don't want their safety to depend on whether they grabbed a bulky autoinjector on the way out the door. I want them to have epinephrine with them, at all times. That's the whole reason Sempresto exists.Join us in building the next generation of anaphylaxis response.Invest or increase your investment today: wefunder.com/sempresto 📱LizElizabeth Reczek, PhDCo-Founder & CEO, SemPresto